FDA expansion for Symdeko in cystic fibrosis
The indication is now for pediatric patients ages six years and older with certain genetic mutations.
Read More
Tag: Symdeko
Vertex secures US approval for Symdeko
US regulators have approved Vertex’ Symdeko, a combination of Kalydeco (ivacaftor) and tezacaftor, to treat certain patients with cystic fibrosis (CF).
Read More
- CERo reports encouraging early data from phase 1 trial of CER‑1236
- ENA Respiratory begins dosing in phase 2 study of INNA‑051 nasal spray
- Argo Biopharma doses first patient in phase 2b trial of BW‑20829
- Akari files new patent and advances second ADC targeting CEACAM5
- BioMed X launches kidney disease project in partnership with the government of Barbados
